The devastating outcomes of the Coronavirus disease 2019 (COVID-19) outbreak have traumatized the world, as they are highly infectious and mainly attack the respiratory tract. Although pregnant women are not at a higher risk of infection, it may result in more severe consequences than in the general population. Treatment of pregnant women with COVID-19 is challenging for doctors, as they need to consider the safety of both the mother and fetus. In addition, there is a lack of knowledge regarding the safety, effectiveness, and possible adverse outcomes of drugs used in COVID-19 pregnant women because they are generally excluded from clinical trials. We briefly reviewed the pathophysiology of drugs currently used in the treatment of COVID-19 in pregnant women and excluded drugs contraindicated during pregnancy. The safety of these drugs is derived from small case studies or clinical trials on other diseases. This article may be useful to physicians, researchers, and people interested in treating COVID-19.
No takes yet. Share an insight, caveat, or question.
Dwivedi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: